Sarepta Therapeutics (SRPT) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tyra Biosciences (TYRA) has outperformed Sarepta Therapeutics (SRPT) over the past year, losing 4.7% versus a loss of 24.6%. Over five years, TYRA leads with a -15.7% price change compared with -83.3% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.43 billion vs $1.39 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRPT | TYRA |
|---|---|---|
| Share price | $13.33 | $20.12 |
| Market cap | $1.43B | $1.39B |
| 1-day change | -5.93% | +1.98% |
| YTD return | -38.06% | -23.47% |
| 1-year return | -24.65% | -4.73% |
| 5-year return | -83.26% | -15.71% |
| P/E ratio (TTM) | 666.50 | — |
| Forward P/E | 8.87 | — |
| EPS (TTM) | $0.02 | $-2.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.20B | — |
| Revenue growth (YoY) | +15.58% | — |
| Net income (latest FY) | $-713.41M | $-119.95M |
| Gross margin | 98.84% | — |
| Operating margin | -31.83% | — |
| Net margin | -32.45% | — |
| 52-week high | $24.68 | $40.65 |
| 52-week low | $13.25 | $18.25 |
| Distance from 52-week high | -45.99% | -50.50% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +63.32% | +135.83% |
| Average volume | 2.70M | 852.56K |
| Shares outstanding | 107.24M | 69.08M |
| Employees | 835 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TYRA has outperformed SRPT by 19.9 percentage points over the past year.
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
SRPT vs TYRA FAQ
Which is bigger, Sarepta Therapeutics or Tyra Biosciences?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.43B compared with $1.39B for Tyra Biosciences (TYRA).
Which stock has performed better over the past year, SRPT or TYRA?
TYRA returned -4.73% over the past 12 months, compared with -24.65% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Sarepta Therapeutics and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.